Inozyme Pharma
Acquired
Pioneering therapies for rare diseases of abnormal mineralization.
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- inozyme.com
- Last Round
- Series AApr 2019
About
Inozyme Pharma, founded in 2017 and headquartered in Boston, Massachusetts, was a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases characterized by abnormal mineralization. The company's lead program, INDEE, targeted ENPP1 deficiency, a life-threatening rare disease affecting the heart, vasculature, and skeleton. With approximately 50 employees, Inozyme went public on Nasdaq (INZY) before being acquired by BioMarin Pharmaceutical in May 2025 for $270 million.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account